⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Figure S7 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Yuying Zhang Jinbang Li Xiaoyu Guo Zhao Gao Ji‐An Pan Sheng Nong Jin-Lin Ma Gang Chen Jiali Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

MHC-II activation boosts T cell responses in head and neck squamous cell carcinoma.
MOC1 cells were engineered using lentivirus to express CIITA for MHC-II construction.
The approach enhances immunotherapy efficacy by targeting T cell activation mechanisms.
Such findings indicate a potential increase in success rates of immunotherapy treatments.

Implication

Observational analysis reveals MHC-II activation of CD4 and CD8 T cells in head and neck cancer, suggesting improved immunotherapy outcomes.

Abstract

Construction of MHC-II in MOC1 cells transfected with lentivirus expressing CIITA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b62 https://doi.org/10.1158/0008-5472.30029710

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Tumor-Specific MHC-II Activates CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy2025
2Figure S6 from Tumor-Specific MHC-II Activates CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy2025
3Figure S1 from Tumor-Specific MHC-II Activates CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy2025
4Figure S2 from Tumor-Specific MHC-II Activates CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy2025
5Table S6 from Tumor-Specific MHC-II Activates CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy2025